Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer

The presence of epidermal growth factor receptor (EGFR) sensitizing mutations predicts suitability for first line EGFR tyrosine kinase inhibitor (TKI) treatment in non-small cell lung cancer (NSCLC). [1 –8] The recommended source for detection of EGFR mutations is a tumour biopsy, but mutations detected in circulating tumour DNA (ctDNA) in the bloodstream can also be used for patient selection [9]. Several methods, with various benefits and disadvantages, exist for the detection of ctDNA [10,11].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research